
|Articles|February 1, 2003
Increased tear production: Restasis approval a milestone for dry eye
The FDA approval of cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan) Dec. 26 marked a landmark for ophthalmology. The eye drop therapy for moderate to severe keratoconjunctivitis sicca is unique in that it treats the inflammatory process that causes the condition, and not just its symptoms.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
How AI is reshaping ophthalmology in 2025 and beyond
2
Glaucoma 2026: Which emerging technologies will change practice?
3
Molecular insights and clinical experience: Extending anti-VEGF durability
4
Reimagining dry eye care: Focus on sustained tear production
5












































